Dental Pulp Stem Cell-Derived Intracellular Vesicles Inhibit OSCC by Delivering PTEN to Suppress PI3K/AKT/mTOR Signalling Pathway

  • Cell Prolif. 2026 Jun 10:e70248. doi: 10.1111/cpr.70248.
Yu Luo  1 Qiang Qin  1 Wenting She  1 Xiangying Wang  1 Xiqin Li  1 Chenxuan Shu  1 Ruohan Li  1 Ziwei Li  1 Dongjie Fu  1 Yan He  2  3 Qingsong Ye  1  3
Affiliations
  • 1. Center of Regenerative Medicine and Department of Stomatology, Renmin Hospital of Wuhan University, Wuhan, China.
  • 2. Institute of Regenerative and Translational Medicine, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, China.
  • 3. Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract

Oral squamous cell carcinoma (OSCC) represents a globally predominant type of oral malignancy with escalating incidence, featuring aggressive biological behaviour, prominent metastatic potential and poor clinical outcomes. Emerging evidence positions dental pulp stem cell-sourced intracellular vesicles (DPSC-IVs) as novel therapeutic vectors in regenerative oncology, citing their low immunogenicity, favourable safety profile and ability to modulate tumour microenvironment. In this study, DPSC-IVs significantly inhibited OSCC progression both in vitro and in vivo, suppressing tumour cell proliferation, invasion and colony formation while simultaneously promoting Apoptosis. Notably, the antitumor effect of DPSC-IVs was further enhanced by combining them with Autophagy inhibitor 3-methyladenine (3-MA), which synergistically suppressed the PI3K/Akt/mTOR pathway and enhanced mitochondrial stress while suppressing residual cytoprotective Autophagy. Mechanistically, DPSC-IVs served as carriers of PTEN into OSCC cells, which in turn suppressed oncogenic PI3K/Akt signalling and induced excessive Mitophagy. Taken together, this study indicated that DPSC-IVs could suppress OSCC through dual mechanisms, highlighting their potential as a promising and clinically translatable therapeutic option with advantages in safety and scalable production.

Keywords
DPSC‐IVs; OSCC; PI3K/AKT/mTOR signalling pathway; PINK1/parkin mediated mitophagy.